Emerald Labs is 100% committed to manufacturing products that are of the highest quality
Disclosures: jintao Xiao: Nothing to Disclose, haiyue He: Nothing to Disclose, ziyi Zhao: Nothing to Disclose, yuhao Zhu: Nothing to Disclose, wenhu Li: Nothing to Disclose, xingyang Luo: Nothing to Disclose, linxiang Zhou: Nothing to Disclose, xiaomei Zhao: Nothing to Disclose, xiaowei Liu: Nothing to Disclose 2385 COMPLICATION-FREE SURVIVAL IN A REAL WORLD COHORT OF PBC PATIENTS: DEEP VERSUS ADEQUATE ALP RESPONSE TO UDCA Anish Reddy 1 Christopher Bowlus 2 Marlyn Mayo 3 Elizabeth Carey 4 Andrea Mospan 5 Aparna Goel 6 Cynthia Levy 7 , 1 University of Miami Miller School of Medicine, 2 University of California, Davis, 3 University of Texas Southwestern Medical Center, 4 Mayo Clinic Arizona, 5 Target RWE, 6 Stanford University Medical Center, 7 University of Miami Background: Current treatment practice for patients with primary biliary cholangitis (PBC) considers achieving serum alkaline phosphatase (ALP) levels below 1.5 times the upper limit of normal after 1 year of treatment with ursodeoxycholic acid (UDCA) an adequate biochemical response
Acute toxicity testing Toxicity tests were performed according to the performance criteria of OECD Guideline 202 (OECD, 2004), with the reconstituted water pH adjusted using the buffer recommendations of Rendal, et al
Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitts lymphoma cells
S2CID 468204
